State Medicaid DUR Board Meeting - Revision 2
This is a Notice Revision
You are currently viewing a revision of a notice. This is a previous copy of a notice that has been published more recently. To view the current version of this notice, click here.
Please Note: Only the files that were associated to this version are included in the Download Attachments section. If that section does not display, all attachments were removed from this version of the notice.
General Information
- Government Type
- State Agency
- Entity
- Department of Health and Human Services (DHHS)
- Public Body
- Drug Utilization Review Board
Notice Information
- Notice Title
- State Medicaid DUR Board Meeting
- Notice Type(s)
- Meeting
- Event Start Date & Time
- September 11, 2025 07:15 AM
- Event End Date & Time
- September 11, 2025 08:30 AM
- Event Deadline Date & Time
- 09/11/25 08:30 AM
- Description/Agenda
- Drug Utilization Review Board Meeting Agenda Thursday, September 11, 2025 7:15 a.m. to 8:30 a.m. Google Meet joining info Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306# Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints. 1) Call to order - Sharon Weinstein, MD a) Welcome and Introductions b) Housekeeping - Luis Moreno, PharmD c) Review and Approval of Minutes 2) Prior Authorization Updates - Luis Moreno, PharmD a) Kebilidi (eladocagene exuparvovec-tneq) b) Yeztugo (lenacapavir) c) Skysona (elivaldogene autotemcel) 3) Public Comment 4) Review Prior Authorization Criteria a) Monoclonal Antibodies for Atopic Dermatitis- Kyu Yun Park, PharmD i) Committee Discussion/Questions ii) Committee Action b) Prophylaxis HAE - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action c) Adzynma (ADAMTS13, recombinant-krhn) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action b) Cablivi (caplacizumab-yhdp) - Skylar Fenton, PharmD i) Committee Discussion/Questions ii) Committee Action c) Piqray (alpelisib) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action d) Nuedexta (dextromethorphan/quinidine) - Luis Moreno, PharmD i) Committee Discussion/Questions ii) Committee Action 5) Next meeting scheduled a) Date: October 9, 2025 b) Topic: Concomitant use of oral buprenorphine-containing products with full-agonist opioids, and the use of oral buprenorphine-containing products (other than Belbucca) for pain. 6) Adjourned - Sharon Weinstein, M
- Notice of Special Accommodations (ADA)
- In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
- Notice of Electronic or Telephone Participation
- Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Meeting Information
- Meeting Location
-
Video/Teleconferencing
Video/Teleconferencing, UT 84116
Show in Apple Maps Show in Google Maps - Contact Name
- Luis Moreno
- Contact Email
- lmoreno@utah.gov
- Contact Phone
- 801-538-6155
Notice Posting Details
- Notice Posted On
- August 28, 2025 04:47 PM
- Notice Last Edited On
- August 28, 2025 05:01 PM
- Deadline Date
- September 11, 2025 08:30 AM